LIFE
EXPLOSION
Our Mission
Our mission is to foster a “Life Explosion” that enriches the lives of people around the world. In pursuit of this mission, we maintain the goal of delivering cures and hope to patients with unmet medical needs.
News
ALL
-
2025.07.17
News
Academic Paper on eNK Cells in “Stem Cell Research and Therapy” Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity
-
2025.04.15
News
R&D Briefing on ARDS (Video), April 9, 2025
-
2025.03.13
News
ONE-BRIDGE Trial in ARDS: Peer-Reviewed Publication in Japan
-
2024.12.12
News
FISCO Corporate Research Report Issued
-
2024.11.18
News
Interview with Mr. Kagimoto published on “Biotech TV”
-
2024.07.03
News
Academic paper on Healios UDC in “Stem Cell Research and Therapy” Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
-
2024.04.09
News
The poster about the presentation of eNK cells research results at AACR Annual Meeting 2024
-
2023.05.23
TOPICS
The poster about the presentation of eNK cells research results at the 26th ASGCT
-
2023.03.20
TOPICS
Presentation of the research results of Healios’ eNK cells and UDCs at the 22nd Congress of the Japanese Society for Regenerative Medicine (March 23-25)
-
2019.09.30
TOPICS
Healios to Present at 2019 Cell & Gene Meeting on the Mesa
-
2019.05.28
TOPICS
Participation at the International Society of Cell and Gene Therapy Conference
-
2019.04.24
TOPICS
Company Presentation at Cell and Gene Meeting on the Medittranean
-
2018.10.24
TOPICS
Seeking interns for Stem cell culture/Transcriptome/Development biology in Japan
-
2018.09.27
TOPICS
Presentation at Cell and Gene Meeting on the Mesa
-
2024.12.12
MEDIA
FISCO Corporate Research Report Issued
-
2023.05.23
MEDIA
The poster about the presentation of eNK cells research results at the 26th ASGCT
-
2023.03.20
MEDIA
Presentation of the research results of Healios’ eNK cells and UDCs at the 22nd Congress of the Japanese Society for Regenerative Medicine (March 23-25)
-
2019.06.06
MEDIA
“Are Stem Cells The Future Of Stroke Treatment?” on Forbes
-
2019.04.25
MEDIA
ONE-BRIDGE study news on “Scrip”
-
2018.10.04
MEDIA
CEO Kagimoto’s interview on “In Vivo”
-
2016.06.28
MEDIA
CEO Kagimoto’s comments on Bloomberg news
-
2025.07.17
ARTICLE/POSTER
Academic Paper on eNK Cells in “Stem Cell Research and Therapy” Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity
-
2025.03.13
ARTICLE/POSTER
ONE-BRIDGE Trial in ARDS: Peer-Reviewed Publication in Japan
-
2024.07.03
ARTICLE/POSTER
Academic paper on Healios UDC in “Stem Cell Research and Therapy” Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
-
2024.04.09
ARTICLE/POSTER
The poster about the presentation of eNK cells research results at AACR Annual Meeting 2024
-
2024.01.17
ARTICLE/POSTER
Publication of JAMA Neurology Article on Clinical Trial for Ischemic Stroke in Japan
-
2023.08.28
ARTICLE/POSTER
Publication of Academic Article on Clinical Trial for ARDS in Japan
-
2023.05.23
ARTICLE/POSTER
The poster about the presentation of eNK cells research results at the 26th ASGCT
Regenerative Medicine
Healios’ Plans For Regenerative Medicine
In The Future
Healios’ strategies for developing innovative therapies
Click here for details
About Regenerative Medicine
The developing paradigm shift for drugs and potential of regenerative medicine
Click here for details
Research and Development Status
- *1 Fast Track and RMAT designations relate to a system that allows for expedited approval of drugs (RMAT is for cellular processed products) that meet certain conditions for the development of new drugs for serious or life-threatening diseases or diseases for which no treatment is available.
- *2 Retinal Pigment Epithelium
- *3 Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer,